share_log

Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO

Benzinga ·  Apr 3 14:45

Abstract Number: 2106

Title: Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)

Session Title: Rapid Oral Abstract – Central Nervous System Tumors
Session Date: June 2, 2024
Session Time: 11:30 AM – 1:00 PM

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment